Business Standard

Samsung looks beyond smartphones to next-gen biologics

The firm makes name as a contract manufacturer of complex medicines to treat diseases like cancer

Samsung, pharmaceutical
Premium

The Samsung group diversified into the pharmaceutical sector in 2011. Now, it’s mobilising its expertise in semiconductor making and engineering know-how to make the way biologics are produced on behalf of Big Pharma more efficient. Photo: Bloomberg

Natasha Khan
The Samsung brand is best known for its smartphones and wide-screen TVs. Yet behind the scenes, the conglomerate is also making a name as a contract manufacturer of complex medicines to treat diseases like cancer.

On a piece of reclaimed land along the western coast of South Korea, Samsung BioLogics Co. is building a $740 million factory that will give it the capacity to become the No. 1 producer by volume of a class of drugs called biologics, many of which are derived from mammal cells.

The Samsung group diversified into the pharmaceutical sector in 2011. Now, it’s mobilising its

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in